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MONOCLONAL ANTIBODIES: A WITNESS SEMINAR IN
CONTEMPORARY MEDICAL HISTORY
by
E. M. TANSEY and P. P. CATTERALL *
"Such cultures could be valuable for medical and industrial use." Thus read the final
sentence ofan immunological paper published in Nature in 1975 by the Argentinian born
Cesar Milstein, and his German post-doctoral fellow, Georges Kohler. Entitled
'Continuous cultures offused cells secreting antibody ofpredefined specificity', the paper,
from Milstein's lab in the MRC Laboratory of Molecular Biology in Cambridge,
announced the discovery of monoclonal antibodies.'
The later debates and recriminations about the apparent "failure" ofBritish science and
technology toexploit this invention tocommercial advantage threw monoclonal antibodies
into a public prominence rarely achieved by scientific discoveries. To a large extent this
has overshadowed the significance ofthe original research and the context in which it was
undertaken.
The history ofthat discovery was the subject ofa witness seminar held by the Wellcome
Trust's History of Twentieth Century Medicine Group in association with the Institute of
Contemporary British History, under the Chairmanship ofSir Christopher Booth. Many of
the key players gathered together to discuss and debate issues associated with the scientific
work, its later exploitation and the nature of scientific discovery. They included Milstein
and Kohler, who shared a Nobel Prize in 1984 for theirdiscovery, their former colleagues,
past and present members of staff of the Medical Research Council and joumalists and
historians.
Antibodies are the proteins produced by lymphocytes that recognize and bind to foreign
substances or antigens in the blood and neutralize them. Each antibody is specific for one
antigen, and is produced by a particular kind of lymphocyte. Hence the latter are
immensely diverse, and purifyirng or extracting a single, defined, antibody was practically
impossible. Monoclonal antibodies are just one, defined and pre-determined kind of
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antibody, produced from a pure single-cell culture line. Their availability had a major
impact on the development of immunology, and on technological and commercial
developments.
The meeting was introduced by Dr Robert Bud, Head of Life and Environmental
Sciences at the Science Museum, who remarked that, whilst contemporary history offers a
rare interaction between subject and viewer, the relationship can be as daunting as it is
exciting. But, he emphasized, that relationship
provides an opportunity for us to have a much more interesting interchange and
identification ofwhat are already understood to be momentous and important changes and
developments. Already it is clear that the emergence ofbiotechnology as a whole is one of
the big shifts in late twentieth century technology.
The term "new biotechnology" had been popularised by the 1984 Office ofTechnology
Assessment Report, Commercial Biotechnology, and this "new biotechnology" stood on
three legs. One, which had quickly been forgotten, comprised new fermentation
technologies. The other two, much better known, were recombinant DNA and hybridoma,
specifically monoclonal antibody, technology.
Bud then examined the contexts of the monoclonal antibody story. Firstly, the tissue
culture work with myelomas and techniques of cell fusion had all been in use in Cesar
Milstein's laboratory in the Medical Research Council's Laboratory ofMolecular Biology
in Cambridge, one of the world's premier bio-medical research Institutes. When the
significance of the achievement was recognized, in the 1980s, questions had immediately
been raised as to who had done the work, typifing the complexities of real scientific
discoveries, which are often difficult to explain to the public.
Secondly [Bud continued], all this happened at a time when other exciting things were
happening in biotechnology. In February 1975, the Asilomar meeting had considered how
one could control the safety of work on recombinant DNA technology. By June 1976 the
NIH had identified regulations by which this work could proceed and by 1976 onwards
enormous amounts of commercial enthusiasm went, particularly in the States, into
biotechnology into recombinant DNA technology. The outcome was many companies,
Genentech was one, Biotech another. So, Milstein and Kohler's paper appeared in the
midst of technological excitement. This had particular meaning in Britain because of a
local history of technological disappointment following a scientific breakthrough. There
was the memory ofthe discovery ofpenicillin and the apparent failure ofBritain to cash in
on it subsequently.
Thus Bud's introduction pointed to two particular aspects of this story for discussion.
Firstly, the nature of the scientific discovery itself, the circumstances and contexts within
which the crucial experiments were performed. Secondly, the commercial application and
technology transfer of monoclonal antibodies, which form the basis of a separate report.
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life: 11 history of fbiotechnology, Cambridge University Press, 1993, esp. pp. 175-6.
3 P. P. Catterall and E. M. Tansey, 'Technology transfer in Britain: the case of monoclonal antibodies',
Coentel)orar Recordl (forthcoming).
323E. M. Tansey and P. P. Catterall
Agreeing with the importance of these issues, Milstein suggested that the scientific
atmosphere and technical competence of the Laboratory of Molecular Biology at
Cambridge had been crucial. He added,
Perhaps even more important is another issue, one that has not been mentioned so far, and
that is why the experiments worked so smoothly and successfully. To what extent were
there elements of coincidence, just pure luck, and to what extent were the experiments
done correctly and logically? I think there were both.
Milstein also wondered whether the applications ofthe hybridoma technology had been
clear in their own minds, or in others' at the time of the discovery. When he and Kohler
had been writing the original paper and considering the final sentence, they had been
hesitant in emphasizing the potential. After much discussion, they had included the remark
because they were convinced that the technique would prove valuable, although he
continued,
I am not saying that we discussed how many zeroes it would be worth at the end of the
equation. I confess I would never have dreamt the number ofzeroes that actually appeared,
probably neither did Georges.
The scientific background of the work was recalled by Professor Kohler, who had
moved to Milstein's lab as a young post-doctoral fellow, having completed a PhD on
antibody heterogeneity at Basle. The mid-I1970s was a period when several ideas about
antibody generation were prominent, especially the "somatic mutation" theory promoted
by Niels Jerne, and the more conventional "germline" hypothesis. Milstein's lab was
experienced in studying myelomas, tumours of the immune system, in mice. Using a
technique developed earlier by Potter, they had established a culture of rapidly
proliferating tumour cells that produced immunoglobulins or antibodies. With Dick
Cotton, Milstein had examined the structure of immunoglobulins, which are composed of
four chains: 2 heavy chains which, like the upright of the letter "Y", constitute the
antibody's constant region and two light chains, which in association with terminal parts
of the heavy chains, like the extended arms of the letter "Y", form the variable region of
the immunoglobin. Using rat/mouse hybrid myelomas, Milstein and Cotton had shown
that the regions of the immunoglobulin were always of one species, although the chains
could be hybrids of both.
The reputation of, and techniques available in, Milstein's lab had drawn Kohler to
Cambridge.
It was the story ofa young scientist looking for a good laboratory, which was exactly what
I found in Cesar Milstein's laboratory. He was working with myeloma P3 which were
growing in culture and had produced the first mutants. I was fascinated by the idea that
you could generate a diversity of antibody specificities by starting with one gene and
diversifying it by mutation.
The technical problem, however, was that myelomas produced antibodies of unknown
specificity. Milstein suggested that Kohler should investigate the antigen specificity of
his myeloma P3 antibodies. Instead, Kohler turned the problem around, trying to generate
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antibodies with defined specificity. Thus, instead of fusing two myelomas, he decided to
fuse one with an antibody-producing cell, a B-lymphocyte. Milstein, Kohler stressed, was
prepared to listen. "He did not dismiss it as out ofreach, the strange idea ofa post-doc, but
he sat down and we discussed the possibilities."
Kohler decided to fuse mouse spleen cells, which are rich in B lymphocytes, with
mouse myeloma cells. Although a rare product ofthe fusion technique the resulting hybrid
cell, or hybridoma, was extremely important. By raising the levels of antibody through
pre-immunization, and then fusing the spleen and myeloma cells, the hybridoma
combined two attributes: the long-living properties of the myeloma, and the specificity of
the antibody. For the first time, then, large quantities ofa pure, specified antibody could be
produced. The first experiment succeeded, Kohler remarking laconically, "We thought
we should make a hybrid, and so I did the fusion, and it worked out very nicely".
This discovery revolutionized the study of immunity and the immune response, and
generated clinical applications. These developments, for which Kohler and Milstein's
discovery was freely available, later led to much debate, discussion and recrimination
about the absence ofpatent protection, an aspect which was discussed by Dr David Secher,
a contemporary of Milstein and Kohler in Cambridge, and later the lab's first industrial
liaison officer, and Dr David Owen, the current director of industrial collaboration of the
MRC.
The scientific aspects were discussed by Sir James Gowans, the distinguished
immunologist and subsequently, in 1977, the Secretary of the MRC, who recalled the
impact of the first announcement of the work.
I don't remember being shattered. I think I was actually at the first meeting where Cesar
talked about his results and I remember being mightily intrigued. I thought it was
extremely ingenious and very interesting and one went away and talked about it and told
one's friends what Cesar had been up to. Some time later when the commercial
possibilities became clear, I remember thinking back to the days when I listened to the
lecture. One was not thinking at the time when one was in the lecture that there was a vast
catalogue of diagnostic reagents just waiting on the horizon, or perhaps even therapy.
These possibilities were certainly not mentioned in the lecture. It was a very interesting,
biologically-illuminating bit of science, but also a method for producing very pure
antibodies, which of course one could see would be important for research. It was a
beautiful piece of science. The media often presents science as a mixture ofbreakthroughs
and disasters but it really doesn't work like that: science is usually a slow chipping away
and every now and again there is a big chip and this was a big chip which we all sat up and
took notice of.
Another eminent immunologist Ita Askonas, commented,
I remember the excitement, although the report ofthe first antigen specific hybridoma was
not shattering. It was not the first time that people thought about trying to do cell-cell
fusions, but this was the first time it was successful. The only real surprise was the fact that
selection of hybridomas producing monoclonal antibodies worked so well and
reproducibly. I have to admit and I think Cesar could tell this story too-that Alan
Williamson and myself had been working some years before, attempting to get
monoclonal antibodies by transferring B-cell clones in vivo. That worked well through
quite a few transfer generations until suddenly the clones started to die-senescence.
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We tried to fuse the clones with transformed cells, using Littlefield's method, but without
success. Therefore I was absolutely thrilled to hear of the achievements of CUsar's
laboratory.4
But, after the first successes, the next set ofexperiments went badly orfailed completely.
Kohler was appointed to the Institute of Immunology at Basle, but neither there nor in
Cambridge would the experiments work. He and Milstein recalled hours on the telephone
and the frequent exchange of serum and cell preparations, Milstein going on to comment,
the reasons actually, probably were different in both cases, and in ours it was quite an
unbelievable situation. We were using something called HAT medium, which is a medium
specially for the selection of hybrids, and in preparation of this medium we kept it in
concentrated form. Now, just before Georges left the lab the concentrated solution was
finished and one of my students prepared a new solution, and this was a concentrated
solution. From there dilutions were prepared here and there in several stages, and it
transpired six months later it took us six months to find out-that that solution, for some
reason which we never found out, was toxic, so instead of selecting cells we were killing
them. That was certainly not the case in your [Kohler's] lab. I don't know why in your
case, it must have been something like that.
The time-course for the success to become apparent was also emphasized by David
Secher:
The firstexperiment worked, but then there were experiments thatdid not work, forreasons
that were not obvious, and there was quite a long time when it did not work and so, with
hindsight of course, there was not a single shattering moment when the paper was
published. Ofcourse, had it not turned out to be reproducible or had it not turned out that
medicine and technology would be so important we would not now be looking back and
talking about when was that single moment?
Many of the seminar participants emphasized that the invention of monoclonal
antibodies relied on many factors: the availability of relevant techniques in an established
laboratory; the conjunction ofajuniorand asenior scientist with synergistic skills, interests
and experience, enabling a new idea to be tried and developed; and the way in which
scientific discoveries build and extend the work of previous generations. Several,
especially the two Nobel Laureates themselves and David Secher, stressed the importance
of pursuing and supporting basic research, and the particular value of the supportive
ambience in the Laboratory of Molecular Biology.
Milstein's own career, from arriving at the LMB as a young Argentinian scientist, had
benefited greatly from the lab's traditions. Employed to work with Fred Sanger, the
proposed collaboration had not been successful, and Sanger encouraged and supported
Milstein in pursuing his own ideas, "Do good experiments and don't worry about anything
else", he told his young protege. No one had stopped him crossing disciplinary
boundaries ordeveloping new ideas. Milstein stressed that dedicated research institutes are
4 J. W. Littlefield, 'Selection of hybrids from matings of fibroblasts "in vitro' and their presumed re-
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critical for the development of good research, suggesting that "laziness is the mother of
good science". In a teaching environment a scientist might be tempted, when faced with
obstacles and difficulties, to devote more of his resources to teaching. But in a pure
research environment, such as the LMB, a scientist had to think and think to get out ofhis
impasse. And both Milstein and Kohler discussed the questions that arose from their
collaboration. Did one make a more substantial contribution than the other? Kohler,
remembering his arrival in Cambridge, cited the ease ofcommunicating with Milstein as
one ofthe attractions ofthe lab. Milstein agreed that this was a major reason for accepting
the younger man into his lab,
Why did I accept him? I had two candidates, and the reason I accepted him was because it
was clear that there was something communicating in our minds. Somehow I felt that we
were talking the same language.
Questions about the respective roles ofthe two scientists hadbecome more explicit when
they shared a Nobel Prize; they had prepared a joint statement to explain their
collaboration.
We agree that both conception and execution of the work was the result of close
collaboration between us, with the skilled technical assistance of Shirley Howe. We are
furtherconvinced that thecombined effect which results from such close collaboration was
of a synergistic nature, synergistic effects taken to mean, as with monoclonal antibodies,
effects which result from the combined action oftwo but which cannot be produced by the
two separately. We both have a most pleasant memory of an exciting period in which a
word, a comment, or a passing remark made by one had a resonant effect on the other. We
do not want such happy memories, which have sealed aclose friendship, to be disturbed by
superficial interpretations of our individual recollections. It was a collaborative work. It
was a collaborative paper. We do not want to make further comments.
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